Short term effectiveness of ustekinumab versus vedolizumab in Crohn’s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis
In CD patients with anti-TNF failure, ustekinumab was more effective than vedolizumab in the short term. These real-world insights contribute to understanding CD management but require validation in larger prospective studies and randomized controlled trials.
Authors
- Mukhtar Alomar (ORCID: https://orcid.org/0000-0001-7798-6881)
- Abdulhamid Althagafi (ORCID: https://orcid.org/0000-0002-1957-1618)
- Turki AlAmeel (ORCID: https://orcid.org/0000-0003-0147-7540)
- Zakia Almudhry
- Ahmad Alamer (ORCID: https://orcid.org/0000-0002-2091-1376)
- Abdulaziz Almulhim (ORCID: https://orcid.org/0000-0002-3727-7543)
- Saad A. Aldosari (ORCID: https://orcid.org/0000-0001-7097-1257)
- Fahad Aldhuwayan
- Saleh Alshouish
- Lina H Al Lehaibi
- Anfal Y Al-Ali
Institutions
- Prince Sattam Bin Abdulaziz University (SA)
- King Abdulaziz University (SA)
- King Fahad Specialist Hospital (SA)
- Zero to Three (US)
- Dhahran Health Center (SA)
- Dammam Central Hospital (SA)
- King Faisal University (SA)
Publication Details
- Journal
- Saudi Journal of Gastroenterology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.4103/sjg.sjg_101_24
- Citations
- 3
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.65